Similar to anakinra, the anti-IL-1β monoclonal antibody canakinumab has reduced disease severity in RA patients, including those unresponsive to anti-TNFα therapies (Alten et al., 2011); however, unlike anakinra, long-term preservation of joint function with canakinumab remains unstudied. The gene discussed is TNF; the disease is rheumatoid arthritis.